Sobi's Altuvoct Drives Strong Q4, Outlook Signals Accelerated Growth
Event summary
- Sobi reported Q4 2025 revenue of SEK 7.821 billion, a 5% increase, or 16% at constant exchange rates (CER).
- Haematology revenue surged 25% at CER, driven by strong sales of Altuvoct (SEK 1.023 billion) and Doptelet (SEK 1.508 billion).
- Immunology revenue grew 2% at CER, with Gamifant and Kineret contributing positively, but offset by a significant decline in Beyfortus royalties.
- The adjusted EBITA margin improved to 41%, excluding items affecting comparability (IAC), and the company anticipates low double-digit revenue growth and mid-30s adjusted EBITA margin in 2026.
- Sobi’s board proposes no dividend payment for the 2025 financial year.
The big picture
Sobi's strong Q4 performance, particularly the surge in haematology revenue driven by Altuvoct and Doptelet, demonstrates the company's ability to capitalize on unmet needs in rare disease treatment. However, the decline in Beyfortus royalties underscores the inherent risks associated with royalty-based revenue and the need for a more diversified product portfolio. The company's ambitious growth outlook signals a strategic shift towards accelerated expansion, but execution risks remain a key consideration for investors.
What we're watching
- Royalty Dependence
- The substantial decline in Beyfortus royalties highlights Sobi's vulnerability to reliance on single-product revenue streams and necessitates diversification efforts.
- Growth Sustainability
- Whether Sobi can sustain its projected low double-digit revenue growth rate in 2026 will depend on continued strong performance from Altuvoct and Doptelet, and successful expansion of its strategic portfolio.
- Margin Pressure
- The anticipated margin compression to the mid-30s percentage range suggests potential cost pressures or pricing challenges that could impact profitability.
Related topics